{
    "clinical_study": {
        "@rank": "112791", 
        "arm_group": [
            {
                "arm_group_label": "AN2728 Topical Ointment, 2%", 
                "arm_group_type": "Experimental", 
                "description": "AN2728 Topical Ointment, 2%, applied twice daily for up to 28 days"
            }, 
            {
                "arm_group_label": "Matching vehicle control", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Matching vehicle control, applied twice daily for up to 28 days"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to investigate the safety and efficacy of AN2728 Topical\n      Ointment, 2% in children, adolescents, and adults (ages 2 years and older) with atopic\n      dermatitis."
        }, 
        "brief_title": "Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Ages 2 Years and Older) With Atopic Dermatitis", 
        "condition": "Dermatitis, Atopic", 
        "condition_browse": {
            "mesh_term": [
                "Dermatitis", 
                "Dermatitis, Atopic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Males or females 2 years and older\n\n          -  Has a clinical diagnosis of AD according to the criteria of Hanifin and Rajka\n\n          -  Has AD involvement \u2265 5% Treatable %BSA (excluding the scalp)\n\n          -  Has an ISGA score of Mild (2) or Moderate (3) at Baseline/Day 1\n\n          -  All female subjects of childbearing potential and male subjects with female partners\n             must use acceptable methods of contraception from the Screening Visit continuously\n             until 30 days after stopping study drug\n\n        Exclusion Criteria:\n\n          -  As determined by the study doctor, a medical history that may interfere with study\n             objectives\n\n          -  Unstable AD or any consistent requirement for high potency topical corticosteroids\n\n          -  History of use of biologic therapy (including intravenous immunoglobulin)\n\n          -  Recent or anticipated concomitant use of systemic or topical therapies that might\n             alter the course of AD\n\n          -  Recent or current participation in another research study\n\n          -  Females who are breastfeeding, pregnant, or with plans to get pregnant during the\n             participation in the study\n\n          -  Participation in a previous AN2728 clinical trial"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "2 Years"
        }, 
        "enrollment": {
            "#text": "750", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 15, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02118766", 
            "org_study_id": "AN2728-AD-301"
        }, 
        "intervention": {
            "arm_group_label": "AN2728 Topical Ointment, 2%", 
            "intervention_name": "AN2728 Topical Ointment, 2%", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "atopic dermatitis", 
        "lastchanged_date": "April 17, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Stockbridge", 
                    "country": "United States", 
                    "state": "Georgia"
                }, 
                "name": "Anacor Investigational Site"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study of the Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Ages 2 Years and Older) With Atopic Dermatitis", 
        "other_outcome": [
            {
                "measure": "Time to improvement in pruritus in the AN2728 treated group compared to the vehicle treated group", 
                "safety_issue": "No", 
                "time_frame": "Through 29 days"
            }, 
            {
                "measure": "Dermatology related QoL scores in the AN2728 treated group compared to the vehicle treated group", 
                "safety_issue": "No", 
                "time_frame": "Day 29"
            }
        ], 
        "overall_contact": {
            "email": "clinicaltrials@anacor.com", 
            "last_name": "Robin Blumenthal, PhD", 
            "phone": "650-223-8597"
        }, 
        "overall_official": {
            "affiliation": "Anacor Pharmaceuticals", 
            "last_name": "Xiaoming Lin, RN, BSN, MS", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Primary Efficacy Endpoint:  Proportion of subjects achieving success in ISGA at Day 29 in the AN2728 treated group compared to the vehicle treated group", 
            "safety_issue": "No", 
            "time_frame": "Day 29"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02118766"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Primary Safety Endpoint:   Frequency of TEAEs, SAEs, and clinically significant changes in vital signs and clinical laboratory parameters in the AN2728 treated group compared to the vehicle treated group", 
                "safety_issue": "Yes", 
                "time_frame": "Through 36 days"
            }, 
            {
                "measure": "Proportion of subjects with an ISGA score of Clear (0) or Almost Clear (1) at Day 29 in the AN2728 treated group compared to the vehicle treated group", 
                "safety_issue": "No", 
                "time_frame": "Day 29"
            }, 
            {
                "measure": "Time to success in ISGA in the AN2728 treated group compared to the vehicle treated group", 
                "safety_issue": "No", 
                "time_frame": "Through 29 days"
            }, 
            {
                "measure": "Change from baseline in signs of AD in the AN2728 treated group compared to the vehicle treated group", 
                "safety_issue": "No", 
                "time_frame": "Day 29"
            }
        ], 
        "source": "Anacor Pharmaceuticals, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Anacor Pharmaceuticals, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}